How Has Genomic Testing Changed Prostate Cancer Treatment?

Dr. Bevan-Thomas discusses how genomic testing has changed prostate cancer treatment

oncotype DX testProstate cancer treatment decisions have changed a lot over the last ten years. One of the challenges that physicians have found over last five years or so is the fact that they are finding more and more lower grade prostate cancers. Physicians see patients who actually have low grade disease, we have intermediate grade disease and we have high grade disease and treatment will depend on the grade of the cancer.

Not being said though, physicians want to make sure that they are not over-treating prostate cancer, but on the flip side of it, they also want to make sure that they are not under-treating it and this is where the essence of where the Oncotype DX test comes into play.

For more, watch Dr. Rich Bevan-Thomas in this video.

Dr. Richard Bevan-Thomas
Dr. Bevan-Thomas is the Medical Director for Prostate Cancer Live. A graduate of Duke University, Rich received both a master’s degree in anatomy and his medical degree from St. Louis University School of Medicine. He completed residency training in urologic surgery at the University of Texas Houston Health Science Center and the renowned MD Anderson Cancer Center, also in Houston. In 2002, he received two top honors in his field; the Pfizer Scholar in Urology and the Gerald G. Murphy Scholar in Urology. Dr. Bevan-Thomas will remain on the leading edge of robotic surgery and cryosurgery at USMD Prostate Cancer Center and will continue offering patients the latest clinical trials in prostate cancer treatment. He continues his teaching and physician proctoring interests as well as instructing in robotic surgery.

This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.

© 2016 Cancer Answers LLC